리툭시맙 - roche.co.kr

Page 1 of 16 2015-07-17-R-15 주 (리툭시맙) 단클론항체, 유전자재조합) / 전문의약품 원료약품 및 그 분량 이 약 1 밀리리터 중

  Roche

아바스틴 베바시주맙 - roche.co.kr

Version: Avastin-2017-05-08-1.0 Korea Product Information

  Avastin

PAT and Quality by Design exemplified in a Mock …

1 PAT and Quality by Design exemplified in a Mock P2 submission for examplain tablets {Part 1: Concept and Principles{Part 2: Mock P2 Submission

  Design, Quality, Tablets, Submissions, And quality by design exemplified, Exemplified, P2 submission for examplain tablets, Examplain

The UniversiTy of sydney HONOURS AT …

The UniversiTy of sydney HONOURS AT GRADUATION, DEANS’ LISTS OF ACADEMIC EXCELLENCE AND PRIZES 2011

  Excellence, 2011, Academic, Graduation, Sydney, Honours, Dean, Prize, Sydney honours at, Sydney honours at graduation, Academic excellence and prizes 2011

The Market Analy sis of Biomarkers - ksbm

Biomaterials Research (2010) 14( 2 ) : 78-85 78 Biomaterials Research The Korean Society for Biomaterials The Market Analy sis of Biomarkers

  Market, Market analy sis of biomarkers, Analy, Biomarkers

제약산업 동향 및 전망 - rating.co.kr

www.rating.co.kr 35 개량신약과 제네릭, 국내사의 주력 제품군 개량신약과 제네릭은 국내 제약사의 주요 제품군으로, 개량신약(Super Generic)은 신약의 화학구조나 제재의 변형(염변경, 신규제재, 용도추가, 복합제 등)을 통하여 특허보호와 약

리툭시맙 - roche.co.kr

Page 1 of 16 2015-07-17-R-15 주 (리툭시맙) 단클론항체, 유전자재조합) / 전문의약품 원료약품 및 그 분량 이 약 1 밀리리터 중

  Roche